Mirum Pharmaceuticals, Inc. - common stock (MIRM) News
Filter MIRM News Items
MIRM News Results
|Loading, please wait...|
MIRM News Highlights
- MIRM's 30 day story count now stands at 7.
- Over the past 13 days, the trend for MIRM's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about MIRM are ARCE, DECK and ED.
Latest MIRM News From Around the Web
Below are the latest news stories about Mirum Pharmaceuticals Inc that investors may wish to consider to help them evaluate MIRM as an investment opportunity.
There's a lot to be optimistic about in the Healthcare sector as 1 analysts just weighed in on and Mirum Pharmaceuticals (MIRM – Research Report) with bullish sentiments. Mirum Pharmaceuticals (MIRM) In a report issued on January 11, Mani Foroohar from Leerink Partners maintained a Buy rating on Mirum Pharmaceuticals. The company's shares closed last Friday at $18.74. According to TipRanks.
Investment company Mesirow Financial Investment Management, Inc. (Current Portfolio) buys Green Brick Partners Inc, Cadre Holdings Inc, Identiv Inc, Atlanticus Holdings Corp, Andersons Inc, sells TriState Capital Holdings Inc, The Joint Corp, Mirum Pharmaceuticals Inc, Genasys Inc, CareDx Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Mesirow Financial Investment Management, Inc..
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Mirum Pharmaceuticals (MIRM – Research Report), with a price target of $64.00. The company's shares closed last Tuesday at $15.92. According to TipRanks.com, Arce is a 4-star analyst with an average return of 14.4% and a 38.4% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Paratek Pharmaceuticals. Mirum Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $57.67.
The following slide deck was published by Mirum Pharmaceuticals, Inc. in conjunction with this event....
FOSTER CITY, Calif., January 11, 2022--Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones
FOSTER CITY, Calif., January 11, 2022--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
FOSTER CITY, Calif., January 04, 2022--Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
Equities research analysts expect Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) to report ($0.06) earnings per share (EPS) for the current quarter, Zacks reports. Five analysts have provided estimates for Mirum Pharmaceuticals earnings. The lowest EPS estimate is ($2.36) and the highest is $1.66. Mirum Pharmaceuticals reported earnings of ($1.43) per share during the same quarter last year, 
No summary available.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Added to NASDAQ Biotechnology Index